Back to Journals » Drug Design, Development and Therapy » Volume 11

Molecular docking, QSAR and ADMET studies of withanolide analogs against breast cancer

Authors Yadav DK, Kumar S, Saloni, Singh H, Kim M, Sharma P, Misra S, Khan F

Received 19 December 2016

Accepted for publication 1 May 2017

Published 22 June 2017 Volume 2017:11 Pages 1859—1870

DOI https://doi.org/10.2147/DDDT.S130601

Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Dr Colin Mak

Peer reviewer comments 3

Editor who approved publication: Dr Qiongyu Guo

Dharmendra K Yadav,1 Surendra Kumar,2 Saloni,1 Harpreet Singh,3 Mi-hyun Kim,1 Praveen Sharma,4 Sanjeev Misra,4 Feroz Khan5

1Department of Pharmacy, College of Pharmacy, Gachon University, Yeonsu-gu, Incheon, Republic of Korea; 2Faculty of Pharmacy, Department of Pharmaceutical Chemistry, Babu Banarasi Das Northern India Institute of Technology, Lucknow, 3Department of Bioinformatics, Indian Council of Medical Research, New Delhi, 4Department of Biochemistry, All India Institute of Medical Sciences, Jodhpur, 5Metabolic & Structural Biology Department, CSIR– Central Institute of Medicinal & Aromatic Plant, Lucknow, India

Abstract: Withanolides are a group of pharmacologically active compounds present in most prodigal amounts in roots and leaves of Withania somnifera (Indian ginseng), one of the most important medicinal plants of Indian traditional practice of medicine. Withanolides are steroidal lactones (highly oxygenated C-28 phytochemicals) and have been reported to exhibit immunomodulatory, anticancer and other activities. In the present study, a quantitative structure activity relationship (QSAR) model was developed by a forward stepwise multiple linear regression method to predict the activity of withanolide analogs against human breast cancer. The most effective QSAR model for anticancer activity against the SK-Br-3 cell showed the best correlation with activity (r2=0.93 and rCV2 =0.90). Similarly, cross-validation regression coefficient (rCV2=0.85) of the best QSAR model against the MCF7/BUS cells showed a high correlation (r2=0.91). In particular, compounds CID_73621, CID_435144, CID_301751 and CID_3372729 have a marked antiproliferative activity against the MCF7/BUS cells, while 2,3-dihydrowithaferin A-3-beta-O-sulfate, withanolide 5, withanolide A, withaferin A, CID_10413139, CID_11294368, CID_53477765, CID_135887, CID_301751 and CID_3372729 have a high activity against the Sk-Br-3 cells compared to standard drugs 5-fluorouracil (5-FU) and camptothecin. Molecular docking was performed to study the binding conformations and different bonding behaviors, in order to reveal the plausible mechanism of action behind higher accumulation of active withanolide analogs with β-tubulin. The results of the present study may help in the designing of lead compound with improved activity.

Keywords: ADMET, breast cancer, QSAR, molecular docking, withanolides
 

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]